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Deep brain stimulation (DBS) is an established therapy for
advanced Parkinson Disease (PD). The widespread application of
DBS and the advancement in research on PD genetics have raised
interest in understanding whether a differential treatment
response in PD patients might be influenced by underlying genetic
mutations [1,2]. To date, literature reports mostly on patients with
frequent mutations. Although PINK1 (PTEN-induced putative ki-
nase 1) is the second most common (2e7% of cases) genetic muta-
tion associated with early-onset PD, the outcome of DBS has only
been described in two patients with homozygous PINK-1mutations
so far [3,4]. PARK-PINK1 is usually considered indistinguishable
from sporadic PD, with a good levodopa response and development
of motor fluctuations and dyskinesia. A characterizing sign may be
the presence of an early-onset lower-limb dystonia [4].
We here describe the case of a patient with homozygous
619C>T-p. (Arg207*) PINK-1 mutation, who underwent bilateral
subthalamic nucleus (STN)-DBS in our centre and was followed-
up for three years (Fig. 1). His medical history was positive for
gout, arterial hypertension, paroxysmal atrial fibrillation, and
post-traumatic L1-L3 fracture. Family history was characterized
by two brothers (out of four) affected by tremor-dominant PD
from the age of 48 and 53, with unknown genetic status.
At the age of 38, in 2003, the patient complained rest tremor of
the right upper limb and anxiety. In 2004, after the diagnosis of PD,
the patient started levodopa with benefit. The [123I]FP-CIT SPECT
(DaTSCAN) showed bilateral reduction in caudate nucleus and
especially in putamen uptake, more remarkable on the left side;
cardiac 131I-MIBG scintigraphy was normal. At the age of 48 the pa-
tient started rotigotine 6 mg/day due to the worsening of motor
symptoms, but developed impulse control disorder (ICD), charac-
terized by binge eating and compulsive video gaming; an attempt
to tapering rotigotine was made, but previous dosage had to be
restored due to the worsening of tremor and bradykinesia. Thirteen
years after symptoms onset (2016), the patient complained severe
motor fluctuations and worsening of motor symptoms; therefore,
he was evaluated for DBS. The levodopa challenge test demon-
strated a 40% improvement of the Movement Disorders Society
Unified Parkinson’s Disease Rating Scale part III (Supplementary
Table 1); despite a Mini Mental State Examination score of 30/30,
the neuropsychological assessment showed a multi-domain
(amnestic and executive) mild cognitive impairment (MCI). The pa-
tient underwent STN-DBS in 2017. The correct positioning of the
electrodes was evaluated by means of post-operative MRI
(Supplementary Fig. 1). A marked lesional effect was observed afterhttps://doi.org/10.1016/j.brs.2021.04.002
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).surgery, with immediate regression of upper limb tremor and
appearance of lower limbs dyskinesias. After DBS activation (bilat-
eral monopolar cathodic stimulation, pulse width 60 us, frequency
130 Hz, amplitude 1.0 mA (left) and 1.2 mA (right)), a marked
improvement on motor symptoms and fluctuations was observed;
LEDD was tapered (Supplementary Table 1). One year after surgery
the patient developed axial and lower limbs dyskinesias and
freezing of gait (FOG), with gait and balance impairment. In the
attempt of ameliorating axial symptoms, the stimulation frequency
was lowered from 130 Hz to 60 Hz, providing an improvement of
gait, with only mild worsening of tremor. Two years after surgery,
the patient experienced worsening of FOG, bradykinesia, upper
limbs tremor, and increased daytime sleepiness; despite improve-
ment of compulsive video-gaming, the patient developed hyper-
phagia determining a weight gain of 20 kg compared with the
presurgical condition. 130 Hz stimulation frequency was restored
obtaining an improvement of tremor and bradykinesia, but wors-
ening of gait. At the three-year post-operative follow-up
(Supplementary Table 1), the patient complained increased dyski-
nesias, sub-continuous tremor, and gait impairment with frequent
falls, mainly due to FOG. However, motor fluctuations were still
relatively controlled, and the patient reported an improvement in
quality of life compared to the presurgical condition
(Supplementary Table 1). Measures of psychiatric symptoms
remained stable and the patient and his caregiver reported good
control of ICD.
The influence of genetic mutations on the DBS outcome is of ut-
termost interest to inform prognosis and tailor treatment, also
considering that genetic mutations tend to be over-represented in
cohorts of DBS patients [5]. Moreover, considering their young
age of onset, good levodopa response, and tendency to developmo-
tor complications, PD patients with PARK-PINK-1 mutations could
represent good candidates for DBS.
To date, there are only two published reports of PD patients car-
riers of homozygous PARK-PINK-1 mutations who underwent DBS,
in one case targeting the STN [3], in the other targeting the Globus
Pallidus internus (GPi) [4]. In both cases, the clinical outcome was
positive (Supplementary Table 1). Cases of heterozygous PINK-1
mutations, sometimes in association with other mutations in PD-
related genes, have been described [1,2,6,7]; however, it is difficult
to understand the influence of these mutations to the clinical
picture.
In contrast to other reported cases, our patient developed axial
symptoms early after surgery. He was treated with low frequency
stimulation to improve FOG and gait; however, after an initially
satisfying response, he reported a worsening of cardinal symptomsunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
Fig. 1. Timeline of clinical evolution and stimulation settings in the reported case. Unified Parkinson’s Disease Rating Scale (UPDRS); The Parkinson’s Disease Questionnaire
Single Index (PDQ-39 SI); Deep Brain Stimulation (DBS); Subthalamic Nucleus (STN); Globus Pallidus Internus (GPi); milliampere (mA), microseconds (msec); Hertz (Hz); Levodopa
equivalent daily dose (LEDD); Dopamine agonists (DA); Left (L); Right (R); Freezing of gait (FOG).
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restoration of 130 Hz.
Our patient suffered from ICD that, despite the impossibility to
withdraw rotigotine, improved significantly after STN-DBS [9]. On
the other hand, he gained over 20 kgs in the years after DBS; weight
gain has already been reported as a side effect of STN-DBS and can
be due to different mechanisms [10]. The non-motor symptoms
burden was not clearly influenced by STN-DBS treatment, and the
Non-Motor Symptoms Scale (NMSS) total score remained substan-
tially unchanged before and after surgery (Supplementary Table 1).
To our knowledge, this is the longest and most comprehensive
follow-up of a PD patient carrier of homozygous PARK-PINK-1
who underwent STN-DBS. We observed an initial benefit that was
followed by worsening of axial symptoms and lower limb involun-
tary movements. One might argue that the decision of considering
STN-DBS in PD patients carriers of PARK-PINK-1 requires a careful
balance between risks and benefits. Nevertheless, our patient re-
ported an overall improvement of quality of life despite the difficult
management, which might justify STN-DBS as a potentially useful
intervention. Further studies including PD patients carriers of
PARK-PINK-1, possibly at different clinical stages, are needed to
clarify the role of STN-DBS in genetic forms of PD.Funding
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